Everolimus- 13 C 2 ,d 4

Overview

Everolimus- 13 C 2 ,d 4 (RAD001- 13 C 2 ,d 4 ) is 13 C labeled Everolimus. Everolimus (RAD001) is a Rapamycin ( HY-10219 ) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy . Everolimus has potent immunosuppressive and anticancer activities.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FKBP | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Isotope-Labeled Compounds

Product Information

• Catalog No.: HY-10218S1
• CAS No.: 1661009-29-5
• Molecular Formula: C5113C2H79D4NO14
• Molecular Weight: 964.23
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source